-

$undefined

N/A

(N/A)

Precision BioSciences NASDAQ:DTIL Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its wholly proprietary ARCUS® genome editing platform. ARCUS is a highly specific and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind. Using ARCUS, the Company's pipeline consists of multiple 'off-the-shelf' CAR T immunotherapy clinical candidates and several in vivo gene correction therapy candidates to cure genetic and infectious diseases where no adequate treatments exist.

Location: 302 E Pettigrew St Ste A100, North Carolina, 27701-2393, United States | Website: precisionbiosciences.com | Industry: Research and Development in Biotechnology | Sector: Professional, Scientific, and Technical Services

Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

-33.74M

Cash

123.6M

Avg Qtr Burn

-16.34M

Short % of Float

3.67%

Insider Ownership

6.78%

Institutional Own.

45.15%

Qtr Updated

06/30/24

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
ECUR-506 Details Ornithine transcarbmylase deficiency	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Azer-cel (PBCAR0191) (azercabtagene zapreleucel) Details Cancer, B-cell lymphoma, Diffuse large B cell lymphoma	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
PBCAR19B (CD19 Allogeneic CAR-T) Details Non-Hodgkin lymphoma, Cancer, Diffuse large B cell lymphoma	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
PBGENE - HBV Details Chronic hepatitis B, Viral infection, Liver disease	Phase 1 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
PBCAR20A (targeting CD20) Details Non-Hodgkin lymphoma, Cancer, Chronic lymphocytic leukemia	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
PBCAR269A (BCMA) Details Cancer, Multiple myeloma	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.